Aimmune Therapeutics Inc (AIMT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2015||Independent Chairman of the Board|
|57||2016||President, Chief Executive Officer, Director|
|57||2017||Chief Financial Officer|
|51||2016||Chief Operating Officer|
|59||2016||Senior Vice President, General Manager of Europe|
- BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment
- BRIEF-Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 Palisade Trial Of AR101 For Peanut Allergy
- BRIEF-Aimmune Therapeutics Inc Files For Potential Mixed Shelf
- BRIEF-Aimmune Therapeutics says CEO Stephen Dilly plans to retire by end of 2018
- UPDATE 1-DBV Technologies peanut allergy drug fails key study